Bayer stock jump 9% as stroke drug trial revives confidence in pipeline

Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical division that has struggled with setbacks and mounting litigation costs. The stock rose more than 9% and traded at €30.30—its highest level in over a week. ...